Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi launch, and highlighted pipeline progress and upcoming catalysts, the analyst tells investors in a research note. The firm says the Amtagvi launch hits total revenue target, but leaned on Proleukin contribution.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics: Strong Financial Performance and Promising Clinical Advancements Drive Buy Rating
- Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges
- Iovance Biotherapeutics price target lowered to $20 from $24 at Baird
- Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler
- Iovance Biotherapeutics: Promising Growth Prospects and Strategic Focus Justify Buy Rating